LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
Index 599Autophagy, 19, 28
aging and, 20, 28
cellular components recycling
and, 20, 28
innate immunity and, 20, 28
Autosomal-dominant (AD), 157
Azacitidine, 125, 130–131
5-azacytidine, 3, 11
Azacytosine nucleosides, 126, 131
5-Aza-2′-deoxycytidine, 11Bacillus Calmette–Guerin (BCG), ́
281
Balloon angioplasty, 173
Barcelona Clinic Liver Cancer
scoring system, 253, 257
Barrett’s esophagus, 243
esophageal cancer and, 142, 145
gastroesophageal reflux and, 238
prevalence of, 232, 238
Basal cell carcinoma, 378, 381
Base excision repair (BER), 11
Basic fibroblast growth factor
(bFGF), 20
Bax/Bak protein, 19, 28
BAX overexpression. in ovarian
cancer, 307, 312
Bayesian methods, in clinical trial,
187, 193
B-cell neoplasm, 415, 429
BCG.SeeBacillus Calmette–Guerin ́
(BCG)
Bcl-2
activation of, 96, 101
inhibitors, 19, 27
protein expression and
oblimersen, 126, 131
Bcl-xL, activation of, 96, 101
BCR-ABL fusion gene
in ALL, 452, 457
in AML, 452, 457
in CML, 452, 457
Bcr/Abl fusion gene, 27
BCS.SeeBreast conserving surgery
(BCS)
Beckwith-Wiedemann syndrome,
405
Benign teratoma, 225, 226
Benzene, 58, 64
leukemia and, 57, 63
metabolism of, 58, 64
myeloperoxidase and, 58, 64
Benzocaine, 77, 81
BEP.SeeBleomycin, etoposide, and
cisplatin (BEP)
BER.SeeBase excision repair
(BER)
Best interest standard, 585
-catenin, 22, 31mutation, in endometrial cancer,
315, 323
Beta-carotene, 198
and cancer reduction, 136, 139
Beta-hCG, 322, 329
Beta-human chorionic
gonadotropin (-hCG), 215,
222
Bethesda guidelines, 137, 140
Bevacizumab, 20, 28
for colorectal cancer treatment,
273, 277
for NSCLC treatment, 206, 211
bFGF.SeeBasic fibroblast growth
factor (bFGF)
-hCG.SeeBeta-human chorionic
gonadotropin (-hCG)
BHD gene mutation, and
Birt-Hogg-Dube syndrome,
280, 289
BH-3 only proteins, 19, 28
Bicalutamide, 128, 284
Bilateral salpingo-oophorectomy
(BSO), 152, 158
in ovarian cancer treatment, 152,
158
Bile duct obstructions, 172
Biliary cancer, adjuvant therapy for,
255, 259
Bim degradation, 27
Biphasic mesothelioma, 485
Birt-Hogg-Dube syndrome, 280,
289
Bisphosphonates
in metastatic bone disease, 512,
515
for reduction in calcium level, 507
Bladder cancer
aromatic amines and, 33, 43
BCG in, 281, 289–290
cisplatin-based multiagent
chemotherapy in, 281, 290
PTEN and, 281, 289
RB1 and, 281, 289
risk factor for, 285, 293
Schistosoma haematobiumand,
285, 293
TP53 and, 281, 289
Bleomycin, and pulmonary toxicity,
558
Bleomycin, etoposide, and cisplatin
(BEP), 298, 302, 313
Bloom syndrome, 4, 12
BMI.SeeBody mass index (BMI)
BNLI.SeeBritish National
Lymphoma Investigation
(BNLI)
Body mass index (BMI), 61, 66
Bone densitometry, 285Bone metastases, radionuclide
treatment of, 511, 514
Bone scintigraphy, 176
Bone tumor, permeative, 368, 372
Bortezomib, 19, 27, 96, 101, 126,
131, 464, 465, 469, 470–471
Bowel obstruction and late
radiation effect, 93
Bowel perforation, and anti-VEGF
therapy, 22, 30
Brachial plexus magnetic resonance
imaging (MRI), 563, 569
Brachytherapy, 88, 93
BRAF mutations
and cetuximab resistance, 97, 102
in melanomas, 377, 381
Brain abscesses, 543, 548
Brain metastasis, 509, 513
improved median survival in
patients with, 510, 514
radiosensitizers for treatment in,
511, 514
Brain necrosis and late radiation
effect, 88, 93
Brain neoplasms, 166, 177
Brain tumors
rehabilitation gains in patients
with, 575, 579
risk for DVT in, 575, 579
BRCA1
impaired activity of, 35, 46
mutation
and breast cancer, 35, 46
and ovarian cancer, 305, 311
and peritoneal carcinomatosis,
480
BRCA2
gene mutation and breast cancer,
152, 158
impaired activity of, 35, 46
pancreatic cancer and, 246, 251
BRCA mutation, 137, 139–140
Breakage-fusion-bridge cycles, 6, 14
Breast cancer
ADH and, 143, 147
alcohol consumption and, 61, 67
anastrazole in, 338, 346
aromatase inhibitor therapy in,
133
ataxia-telangiectasia and, 60, 65
autologous stem cell
transplantation and, 536
bevacizumab, 337, 346
BRCA1 and, 35, 46, 305, 311,
328, 331, 341
BRCA2 gene mutation and, 152,
158
causes of, 331, 341
chemotherapy for, 337, 346